FDA closed 2024 with several notable regulatory decisions

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. Healthy Eating, Simplified Kickstart your healthy habits in the New Year with Green Chef!   Get 50% off your first box and enjoy free salads for the first 2 months.   New Year, New You - Begin Your Journey Today! Join Now!

Featured News

Top Priorities and Challenges for Digital Health Leaders in 2025: 5 Key Insights About 79% of digital health leaders said their companies are pursuing new investment capital in the next year, according to a recent survey from Summit Health Advisors. AI Developers Need Real-World Data — and Atropos Health Is Stepping Up to Help Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries. Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program. Healthcare IT in 2025: Triage for the Age of AI Amid the chaos and confusion of healthcare IT in our age of AI, a triage concept may be the best guide for organizations fighting to stray strong and capable in 2025 and beyond. The Evolving Landscape of Medicaid and CHIP: Implications for Children's Oral Health Medicaid and CHIP facilitate necessary access to oral health services, which helps to bridge the gap in dental care for children from low- and moderate-income families. By providing coverage, it ensures that socioeconomic status does not hinder a child's ability to receive necessary dental services.

Resources

MedCity FemFwd: How Celmatix is Using ARPA-H's Sprint for Women's Health Funding In this episode, we're joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women's health biotech company. Celmatix was recently awarded $3.5 million from the Advanced Research Projects Agency for Health (ARPA-H) through the Sprint for Women's Health program. In this episode, Beim discusses how Celmatix will be using the funding. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe